ACET Jul 2024 2.500 call
| Previous Close | 0.1000 |
| Open | 0.1000 |
| Bid | 0.0000 |
| Ask | 0.1000 |
| Strike | 2.50 |
| Expire Date | 2024-07-19 |
| Day's Range | 0.1000 - 0.1000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 173 |
Business WireAdicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif. & BOSTON, May 31, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on May 31, 2024.
Business WireAdicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference
REDWOOD CITY, Calif. & BOSTON, May 29, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference being held from June 5-6, 2024 in New York.
Business WireAdicet Reports First Quarter 2024 Financial Results and Provides Business Updates
REDWOOD CITY, Calif. & BOSTON, May 14, 2024--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2024.
